New pill for chronic hives tested in thousands of patients

This study follows about 3,280 adults with chronic spontaneous urticaria (CSU) to see how well remibrutinib controls their hives in everyday medical practice. Participants either continue standard antihistamines or switch to remibrutinib, and researchers track symptom control and safety for 24 months. The goal is to understand if remibrutinib works better than usual care in a broad, real-world patient group.